Kopp Investment Advisors LLC cut its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 10.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 406,444 shares of the medical research company’s stock after selling 47,904 shares during the quarter. NeoGenomics comprises approximately 3.6% of Kopp Investment Advisors LLC’s portfolio, making the stock its 6th biggest holding. Kopp Investment Advisors LLC owned approximately 0.51% of NeoGenomics worth $3,601,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NEO. GSA Capital Partners LLP acquired a new stake in shares of NeoGenomics in the third quarter valued at about $369,000. Bank of New York Mellon Corp grew its stake in shares of NeoGenomics by 4.1% in the third quarter. Bank of New York Mellon Corp now owns 982,560 shares of the medical research company’s stock valued at $10,935,000 after buying an additional 38,776 shares in the last quarter. Emerald Advisers Inc. PA grew its stake in shares of NeoGenomics by 3.1% in the fourth quarter. Emerald Advisers Inc. PA now owns 1,424,263 shares of the medical research company’s stock valued at $12,619,000 after buying an additional 42,790 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of NeoGenomics by 79.2% in the second quarter. Goldman Sachs Group Inc. now owns 30,678 shares of the medical research company’s stock valued at $275,000 after buying an additional 13,561 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of NeoGenomics by 50.3% in the third quarter. Janus Henderson Group PLC now owns 3,464,655 shares of the medical research company’s stock valued at $38,562,000 after buying an additional 1,159,888 shares in the last quarter. Hedge funds and other institutional investors own 84.72% of the company’s stock.
Shares of NeoGenomics, Inc. (NASDAQ NEO) opened at $8.71 on Monday. NeoGenomics, Inc. has a 12 month low of $7.08 and a 12 month high of $11.63. The company has a current ratio of 2.14, a quick ratio of 1.99 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $700.37, a P/E ratio of 145.17, a price-to-earnings-growth ratio of 4.84 and a beta of 0.47.
A number of research firms have recently issued reports on NEO. ValuEngine lowered NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. Royal Bank of Canada set a $23.00 target price on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Finally, Scotiabank set a $22.00 target price on NeoGenomics and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.83.
WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/12/neogenomics-inc-neo-position-trimmed-by-kopp-investment-advisors-llc.html.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.